Evidence map›Paper›PMID 36386039›Full record

ArticleEClinicalMedicine2023

Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: A multicentre cohort study.

Shaobo Mo, Weixing Dai, Hui Wang, Xiaoliang Lan, Chengcheng Ma, Zhixi Su, Wenqiang Xiang, Lingyu Han, Wenqin Luo, Long Zhang and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03737591 (The Implication of Plasma Circulating Tumor DNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas), which is not on this map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03737591 completednot on this map

The Implication of Plasma Circulating Tumor DNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas: a Multicenter, Cohort Study

TypeobservationalSponsorFudan UniversityRan2010 to 2021Enrolled1,138ConditionsColorectal Cancer, AdenomaArmsNext-generation sequencing (NGS)
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shaobo MoDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weixing DaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui WangSinglera Genomics (Shanghai) Ltd, Shanghai, China.
Xiaoliang LanDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chengcheng MaSinglera Genomics (Shanghai) Ltd, Shanghai, China.
Zhixi SuSinglera Genomics (Shanghai) Ltd, Shanghai, China.
Wenqiang XiangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Lingyu HanDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenqin LuoDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Long ZhangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Renjie WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yaodong ZhangDepartment of Intensive Care Unit, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenming ZhangDepartment of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin YangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying ZhengDepartment of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, China.
Mingzhu HuangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ye XuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Li LiangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Sanjun CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Guoxiang CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early detection and prognosis prediction of colorectal cancer (CRC) can significantly reduce CRC-related mortality. Recently, circulating tumour DNA (ctDNA) methylation has shown good application foreground in the early detection and prognosis prediction of multiple tumours. Methods: This multicentre cohort study evaluated ctDNA methylation haplotype patterns based on archived plasma samples (collected between 2010 and 2018) from 1138 individuals at two medical centres: Fudan University Shanghai Cancer Center (Shanghai, China) and Southern Medical University Nanfang Hospital (Guangzhou, Guangdong, China), including 366 healthy individuals, 182 patients with advanced adenoma (AA), and 590 patients with CRC. Samples were processed using the ColonES assay, a targeted bisulfite sequencing method that detects ctDNA methylation haplotype patterns in 191 genomic regions. Among these 1138 samples, 748 were used to develop a classification model, and 390 served as a blinded cohort for independent validation. The study is registered at https://register.clinicaltrials.gov with the unique identifier NCT03737591. Results: The model obtained from unblinded samples discriminated patients with CRC or AA from normal controls with high accuracy. In the blinded validation set, the ColonES assay achieved sensitivity values of 79.0% (95% confidence interval (CI), 66%-88%) in AA patients and 86.6% (95% CI, 81%-91%) in CRC patients with a specificity of 88.1% (95% CI, 81%-93%) in healthy individuals. The model area under the curve (AUC) for the blinded validation set was 0.903 for AA samples and 0.937 for CRC samples. Additionally, the prognosis of patients with high preoperative ctDNA methylation levels was worse than that of patients with low ctDNA methylation levels (p = 0.001 for relapse-free survival and p = 0.004 for overall survival). Interpretation: We successfully developed and validated an accurate, noninvasive detection method based on ctDNA methylation haplotype patterns that may enable early detection and prognosis prediction for CRC. Funding: The Grant of National Natural Science Foundation of China (No.81871958), National Natural Science Foundation of China (No. 82203215), Shanghai Science and Technology Committee (No. 19140902100), Scientific Research Fund of Fudan University (No.IDF159052), Shanghai Municipal Health Commission (SHWJRS 2021-99), and Shanghai Sailing Program (22YF1408800).

Indexed as

Colorectal cancerctDNA methylationEarly detectionPrecancerous adenomasPrognosis prediction

Identifiers

PMID36386039
PMCPMC9646872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.